BEND, Ore., June 27, 2011 /PRNewswire-USNewswire/ — Bend
Research Inc. (www.bendresearch.com), a
leading independent drug-formulation development and manufacturing
company, has named a new president.
Jim Nightingale, who has worked at the company since 1993, will
be the fourth president in the firm’s 36-year history.
Nightingale will succeed Rod Ray, who will continue in his
capacity as Bend Research Chief Executive Officer (CEO) and
chairman of the board of directors.
Ray announced Nightingale’s promotion from Senior Vice President
for Business Development and Strategic Alliances, calling the new
president “a dogged pursuer of quality and timeliness for our
customers.”
“Jim cares deeply about the company and our mission of advancing
our clients’ best new medicines,” Ray said.
He credited Nightingale with being instrumental in developing
and implementing the business development strategy that transformed
the company from an exclusive relationship with Pfizer to the
multiclient success it now enjoys. In the two years since Bend
Research and Pfizer ended the exclusive contract, the company has
built a base of more than 70 clients, including most of the largest
pharmaceutical companies in the world.
Nightingale will be responsible for nearly all operational
aspects of the company, working with Ray and Lisa Graham, the
company’s Chief Operating Officer (COO). His business development
duties will be assumed by David Lyon, Vice
President—Research.
The changes free Ray to focus more on strategic planning and
future opportunities for the company. Ray served as president of
the privately held company since 2002. Previous presidents were
Chris Babcock (1987-2002) and Harry Lonsdale (1975-1987).
Nightingale holds a master’s degree and doctorate in
bioengineering from the University of Washington, where he also
received a bachelor’s degree in chemical engineering
‘/>”/>
